Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fallCNBC • 10/31/24
Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses?Investors Business Daily • 10/31/24
Exploring Analyst Estimates for Merck (MRK) Q3 Earnings, Beyond Revenue and EPSZacks Investment Research • 10/28/24
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)Business Wire • 10/28/24
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda ThreatSeeking Alpha • 10/25/24
Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic CancersBusiness Wire • 10/24/24
CDC'S ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and OlderBusiness Wire • 10/23/24
Gilead, MRK Report Data From Investigational Combination Study for HIVZacks Investment Research • 10/21/24
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Business Wire • 10/19/24